STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Advance in Molecular Engineering Review Article

Organometallic Osmium Compounds in Cancer Therapy

  1. A. Mohamed Sikkander Department of Chemistry, Velammal Engineering College
  2. Rajeev Ranjan Department of Chemistry, DSPM University
  3. A. Mohamed Sikkander Department of Electronics & Telecommunication, Thakur College of Engineering

Abstract

The exploration of organometallic complexes with osmium as potential anticancer agents was indeed an area of ongoing research. These complexes were being investigated for their unique properties and mechanisms of action against cancer cells. However, it’s essential to note that the field of scientific research is dynamic, and new findings may have emerged since then. Organometallic complexes with osmium can be designed to exhibit specific features that make them promising candidates for anticancer applications. These features may include the ability to interact with cellular components, induce DNA damage, or modulate specific pathways crucial for cancer cell survival. To get the most current and accurate information on the latest developments in this field, I recommend checking recent scientific literature, research articles, and updates from reputable sources. Researchers often publish their findings in peer-reviewed journals, and these publications provide valuable insights into the progress of studies involving osmium-based organometallic complexes in cancer research and treatment. KP1339, also known as tetrachloride (dimethyl sulfoxide) (1H-indazole) ruthenate (III), is an osmium (III) compound that has been studied for its potential anticancer properties. It belongs to the class of organometallic compounds and has been investigated for its ability to induce cancer cell death and inhibit tumor growth. Osmium (II) arene complexes are a class of organometallic compounds that involve osmium in the +2-oxidation state coordinated with arene ligands. The structural characteristics and coordination environment of osmium (II) arene complexes make them interesting subjects of study for their potential applications, particularly in the field of medicinal chemistry and cancer research.

Keywords

References (164)

  1. Johnstone TC, Suntharalingam K, Lippard SJ. Third row transition metals for the treatment of cancer. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences. 2015;373(2037):20140185. doi:10.1098/rsta.2014.0185
  2. Bruijnincx PCA, Sadler PJ. Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. Advances in Inorganic Chemistry. 2009:1-62. doi:10.1016/s0898-8838(09)00201-3
  3. van Rijt SH, Romero-Canelón I, Fu Y, Shnyder SD, Sadler PJ. Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells. Metallomics. 2014;6(5):1014. doi:10.1039/c4mt00034j
  4. Florea AM, Büsselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers. 2011;3(1):1351-1371. doi:10.3390/cancers3011351
  5. Frezza, M.; Hindo, S.; Chen, D.; Davenport, A.; Schmitt, S.; Tomco, D.; Dou, Q.P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des. 2010, 16, 1813–1825.
  6. Aoki K, Murayama K. Nucleic Acid-Metal Ion Interactions in the Solid State. Metal Ions in Life Sciences. 2011:43-102. doi:10.1007/978-94-007-2172-2_2
  7. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Critical Reviews in Oncology/Hematology. 2002;42(3):317-325. doi:10.1016/s1040-8428(01)00219-0
  8. Che CM, Siu FM. Metal complexes in medicine with a focus on enzyme inhibition. Current Opinion in Chemical Biology. 2010;14(2):255-261. doi:10.1016/j.cbpa.2009.11.015
  9. Chen D, Milacic V, Frezza M, Dou Q. Metal Complexes, their Cellular Targets and Potential for Cancer Therapy. Current Pharmaceutical Design. 2009;15(7):777-791. doi:10.2174/138161209787582183
  10. Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, et al. Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development. Anti-Cancer Agents in Medicinal Chemistry. 2010;10(4):272-282. doi:10.2174/187152010791162270
  11. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. European Journal of Cancer. 1998;34(10):1522-1534. doi:10.1016/s0959-8049(98)00224-x
  12. Olszewski U, Hamilton G. A Better Platinum-Based Anticancer Drug Yet to Come? Anti-Cancer Agents in Medicinal Chemistry. 2010;10(4):293-301. doi:10.2174/187152010791162306
  13. Shah N, Dizon DS. New-Generation Platinum Agents for Solid Tumors. Future Oncology. 2009;5(1):33-42. doi:10.2217/14796694.5.1.33
  14. Günes DA, Florea AM, Splettstoesser F, Büsselberg D. Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity. NeuroToxicology. 2009;30(2):194-202. doi:10.1016/j.neuro.2008.12.001
  15. Tsang RY, Al-Fayea T, Au HJ. Cisplatin Overdose. Drug Safety. 2009;32(12):1109-1122. doi:10.2165/11316640-000000000-00000
  16. Knoll C, Smith RJ, Shores C, Blatt J. Hearing genes and cisplatin deafness: a pilot study. Laryngoscope. 2006 Jan;116(1):72-4. doi:10.1097/01.mlg.0000185596. 20207.d2. PMID: 16481813.
  17. Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJW, et al. Relationship Between Cisplatin Administration and the Development of Ototoxicity. Journal of Clinical Oncology. 2006;24(6):918-924. doi:10.1200/jco.2006.10.077
  18. Drottar M, Liberman MC, Ratan RR, Roberson DW. The Histone Deacetylase Inhibitor Sodium Butyrate Protects Against Cisplatin‐Induced Hearing Loss in Guinea Pigs. The Laryngoscope. 2006;116(2):292-296. doi:10.1097/01.mlg.0000197630.85208.36
  19. Momekov G, Ferdinandov D, Bakalova A, Zaharieva M, Konstantinov S, Karaivanova M. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands. Archives of Toxicology. 2006;80(9):555-560. doi:10.1007/s00204-006-0078-0
  20. Liu M, Chien CC, Burne-Taney M, Molls RR, Racusen LC, Colvin RB, et al. A Pathophysiologic Role for T Lymphocytes in Murine Acute Cisplatin Nephrotoxicity. Journal of the American Society of Nephrology. 2006;17(3):765-774. doi:10.1681/asn.2005010102
  21. Masubuchi Y, Kawasaki M, Horie T. Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats. Archives of Toxicology. 2006;80(6):347-353. doi:10.1007/s00204-006-0079-z
  22. Ralph SJ, Neuzil J. Mitochondria as targets for cancer therapy. Molecular Nutrition & Food Research. 2009;53(1):9-28. doi:10.1002/mnfr.200800044
  23. Brozovic A, Ambriović-Ristov A, Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Critical Reviews in Toxicology. 2010;40(4):347-359. doi:10.3109/10408441003601836
  24. Desoize B. Cancer and Metals and Metal Compounds:. Critical Reviews in Oncology/Hematology. 2002;42(1):1-3. doi:10.1016/s1040-8428(02)00017-3
  25. Jordan P, Carmo-Fonseca* M. Molecular mechanisms involved in cisplatin cytotoxicity. Cellular and Molecular Life Sciences. 2000;57(8):1229-1235. doi:10.1007/pl00000762
  26. Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways. Current Medicinal Chemistry-Anti-Cancer Agents. 2005;5(3):251-265. doi:10.2174/1568011053765967
  27. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Critical Reviews in Oncology/Hematology. 2005;53(1):3-11. doi:10.1016/j.critrevonc.2004.08.008
  28. Schar P. SMC1 coordinates DNA double-strand break repair pathways. Nucleic Acids Research. 2004;32(13):3921-3929. doi:10.1093/nar/gkh716
  29. Brabec V, Kasparkova J. Modifications of DNA by platinum complexes. Drug Resistance Updates. 2005;8(3):131-146. doi:10.1016/j.drup.2005.04.006
  30. Kim JH, Reeder E, Parkin S, Awuah SG. Gold(I/III)-Phosphine Complexes as Potent Antiproliferative Agents. Scientific Reports. 2019;9(1). doi:10.1038/s41598-019-48584-5
  31. Gasser G, Ott I, Metzler-Nolte N. Organometallic Anticancer Compounds. Journal of Medicinal Chemistry. 2010;54(1):3-25. doi:10.1021/jm100020w
  32. Frei A, Verderosa AD, Elliott AG, Zuegg J, Blaskovich MAT. Metals to combat antimicrobial resistance. Nature Reviews Chemistry. 2023;7(3):202-224. doi:10.1038/s41570-023-00463-4
  33. Berndsen RH, Weiss A, Abdul UK, Wong TJ, Meraldi P, Griffioen AW, et al. Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. Scientific Reports. 2017;7(1). doi:10.1038/srep43005
  34. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). Journal of Inorganic Biochemistry. 2006;100(5-6):891-904. doi:10.1016/j.jinorgbio.2006.02.013
  35. Wernitznig D, Kiakos K, Del Favero G, Harrer N, Machat H, Osswald A, et al. First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. Metallomics. 2019;11(6):1044-1048. doi:10.1039/c9mt00051h
  36. Alessio E, Messori L. NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. Molecules. 2019;24(10):1995. doi:10.3390/molecules24101995
  37. Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Körner W, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer. 2013;49(15):3366-3375. doi:10.1016/j.ejca.2013.05.018
  38. Flocke LS, Trondl R, Jakupec MA, Keppler BK. Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines. Investigational New Drugs. 2016;34(3):261-268. doi:10.1007/s10637-016-0337-8
  39. Dhyani P, Quispe C, Sharma E, Bahukhandi A, Sati P, Attri DC, et al. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell International. 2022;22(1). doi:10.1186/s12935-022-02624-9
  40. Xu X, Dai F, Mao Y, Zhang K, Qin Y, Zheng J. Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1242488
  41. Anthony EJ, Bolitho EM, Bridgewater HE, Carter OWL, Donnelly JM, Imberti C, et al. Metallodrugs are unique: opportunities and challenges of discovery and development. Chemical Science. 2020;11(48):12888-12917. doi:10.1039/d0sc04082g
  42. Asperti M, Cantamessa L, Gryzik M, Bugatti M, Codenotti S, Denardo A, et al. The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo. Clinical and Experimental Medicine. 2023;23(6):2487-2502. doi:10.1007/s10238-023-01012-5
  43. Bergamo A, Sava G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Transactions. 2011;40(31):7817. doi:10.1039/c0dt01816c
  44. Cui XY, Park SH, Park WH. Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels. Molecules. 2022;27(16):5207. doi:10.3390/molecules27165207
  45. Delgobo M, Gonçalves RM, Delazeri MA, Falchetti M, Zandoná A, Nascimento das Neves R, et al. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. Free Radical Biology and Medicine. 2021;177:58-71. doi:10.1016/j.freeradbiomed.2021.10.020
  46. Dwyer BG, Johnson E, Cazares E, McFarlane Holman KL, Kirk SR. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNAPhe. Journal of Inorganic Biochemistry. 2018;182:177-183. doi:10.1016/j.jinorgbio.2018.02.019
  47. Elie BT, Pechenyy Y, Uddin F, Contel M. A heterometallic ruthenium–gold complex displays antiproliferative, antimigratory, and antiangiogenic properties and inhibits metastasis and angiogenesis-associated proteases in renal cancer. JBIC Journal of Biological Inorganic Chemistry. 2018;23(3):399-411. doi:10.1007/s00775-018-1546-8
  48. Figueroa-DePaz Y, Pérez-Villanueva J, Soria-Arteche O, Martínez-Otero D, Gómez-Vidales V, Ortiz-Frade L, et al. Casiopeinas of Third Generations: Synthesis, Characterization, Cytotoxic Activity and Structure–Activity Relationships of Mixed Chelate Compounds with Bioactive Secondary Ligands. Molecules. 2022;27(11):3504. doi:10.3390/molecules27113504
  49. Guzmán-Méndez Ó, González F, Bernès S, Flores-Álamo M, Ordóñez-Hernández J, García-Ortega H, et al. Coumarin Derivative Directly Coordinated to Lanthanides Acts as an Excellent Antenna for UV–Vis and Near-IR Emission. Inorganic Chemistry. 2018;57(3):908-911. doi:10.1021/acs.inorgchem.7b02861
  50. Annaraj J, Srinivasan S, Ponvel KM, Athappan P. Mixed ligand copper(II) complexes of phenanthroline/bipyridyl and curcumin diketimines as DNA intercalators and their electrochemical behavior under Nafion® and clay modified electrodes. Journal of Inorganic Biochemistry. 2005;99(3):669-676. doi:10.1016/j.jinorgbio.2004.11.018
  51. Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Körner W, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer. 2013;49(15):3366-3375. doi:10.1016/j.ejca.2013.05.018
  52. Kydd J, Jadia R, Velpurisiva P, Gad A, Paliwal S, Rai P. Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems. Pharmaceutics. 2017;9(4):46. doi:10.3390/pharmaceutics9040046
  53. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016;66(1):7-30. doi:10.3322/caac.21332
  54. Weinstein IB, Joe AK. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clinical Practice Oncology. 2006;3(8):448-457. doi:10.1038/ncponc0558
  55. Ji W, Sun B, Su C. Targeting MicroRNAs in Cancer Gene Therapy. Genes. 2017;8(1):21. doi:10.3390/genes8010021
  56. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends in Molecular Medicine. 2015;21(4):223-232. doi:10.1016/j.molmed.2015.01.001
  57. Sudhakar A. History of Cancer, Ancient and Modern Treatment Methods. Journal of Cancer Science & Therapy. 2009;01(02):i-iv. doi:10.4172/1948-5956.100000e2
  58. Jahanban‐Esfahlan R, Seidi K, Banimohamad‐Shotorbani B, Jahanban‐Esfahlan A, Yousefi B. Combination of nanotechnology with vascular targeting agents for effective cancer therapy. Journal of Cellular Physiology. 2017;233(4):2982-2992. doi:10.1002/jcp.26051
  59. Kydd J, Jadia R, Velpurisiva P, Gad A, Paliwal S, Rai P. Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems. Pharmaceutics. 2017;9(4):46. doi:10.3390/pharmaceutics9040046
  60. Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Advanced Drug Delivery Reviews. 2018;130:17-38. doi:10.1016/j.addr.2018.07.007
  61. Ertas YN, Abedi Dorcheh K, Akbari A, Jabbari E. Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells: A Review of Recent Advances. Nanomaterials. 2021;11(7):1755. doi:10.3390/nano11071755
  62. Dai Y, Xu C, Sun X, Chen X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chemical Society Reviews. 2017;46(12):3830-3852. doi:10.1039/c6cs00592f
  63. Swain S, Sahu P, Beg S, Babu S. Nanoparticles for Cancer Targeting: Current and Future Directions. Current Drug Delivery. 2016;13(8):1290-1302. doi:10.2174/1567201813666160713121122
  64. Yuan D, Zhao Y, Banks WA, Bullock KM, Haney M, Batrakova E, et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials. 2017;142:1-12. doi:10.1016/j.biomaterials.2017.07.011
  65. Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacologica Sinica. 2017;38(6):754-763. doi:10.1038/aps.2017.12
  66. Siafaka P, Üstündağ Okur N, Karavas E, Bikiaris D. Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses. International Journal of Molecular Sciences. 2016;17(9):1440. doi:10.3390/ijms17091440
  67. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology. 2022;29(5):3044-3060. doi:10.3390/curroncol29050247
  68. Boros E, Dyson PJ, Gasser G. Classification of Metal-Based Drugs according to Their Mechanisms of Action. Chem. 2020;6(1):41-60. doi:10.1016/j.chempr.2019.10.013
  69. Hartinger CG, Jakupec MA, Zorbas‐Seifried S, Groessl M, Egger A, Berger W, et al. KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chemistry & Biodiversity. 2008;5(10):2140-2155. doi:10.1002/cbdv.200890195
  70. Savic M, Milovanovic M, Stankovic V, Mihajlovic K, Turnic TN, Simovic AR, et al. The Antitumor and Toxicity Effects of Ruthenium(II) Complexes on Heterotopic Murine Colon Carcinoma Model. Experimental and Applied Biomedical Research (EABR). 2025;26(3):233-243. doi:10.2478/sjecr-2022-0028
  71. Mestroni G, Alessio E, Sava G, Pacor S, Coluccia M, Boccarelli A. Water‐Soluble Ruthenium(III)‐Dimethyl Sulfoxide Complexes:Chemical Behaviour and Pharmaceutical Properties. Metal-Based Drugs. 1993;1(1):41-63. doi:10.1155/mbd.1994.41
  72. Ravera M, Bagni G, Mascini M, Osella D. DNA-Metallodrugs Interactions Signaled by Electrochemical Biosensors: An Overview. Bioinorganic Chemistry and Applications. 2007;2007:1-11. doi:10.1155/2007/91078
  73. Qin QP, Wang ZF, Huang XL, Tan MX, Shi BB, Liang H. High in Vitro and in Vivo Tumor-Selective Novel Ruthenium(II) Complexes with 3-(2′-Benzimidazolyl)-7-fluoro-coumarin. ACS Medicinal Chemistry Letters. 2019;10(6):936-940. doi:10.1021/acsmedchemlett.9b00098
  74. Zhang X, Cheng L, Lu Y, Tang J, Lv Q, Chen X, et al. A MXene-Based Bionic Cascaded-Enzyme Nanoreactor for Tumor Phototherapy/Enzyme Dynamic Therapy and Hypoxia-Activated Chemotherapy. Nano-Micro Letters. 2021;14(1). doi:10.1007/s40820-021-00761-w
  75. Sava G, Bergamo A. Ruthenium-based compounds and tumour growth control (review). International Journal of Oncology. 2000. doi:10.3892/ijo.17.2.353
  76. Nabiyeva T, Marschner C, Blom B. Synthesis, structure and anti-cancer activity of osmium complexes bearing π-bound arene substituents and phosphane Co-Ligands: A review. European Journal of Medicinal Chemistry. 2020;201:112483. doi:10.1016/j.ejmech.2020.112483
  77. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017;3(4):651-657. doi:10.1016/j.trci.2017.10.005
  78. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs. Clinical Pharmacology & Therapeutics. 2010;87(3):272-277. doi:10.1038/clpt.2009.295
  79. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 2010;9(3):203-214. doi:10.1038/nrd3078
  80. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Research & Therapy. 2014;6(4). doi:10.1186/alzrt269
  81. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020;25(24):5789. doi:10.3390/molecules25245789
  82. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery. 2014;13(6):419-431. doi:10.1038/nrd4309
  83. Owens PK, Raddad E, Miller JW, Stille JR, Olovich KG, Smith NV, et al. A decade of innovation in pharmaceutical R&D: the Chorus model. Nature Reviews Drug Discovery. 2014;14(1):17-28. doi:10.1038/nrd4497
  84. Drews JR. Drug Discovery: A Historical Perspective. Science. 2000;287(5460):1960-1964. doi:10.1126/science.287.5460.1960
  85. Sams-Dodd F. Target-based drug discovery: is something wrong? Drug Discovery Today. 2005;10(2):139-147. doi:10.1016/s1359-6446(04)03316-1
  86. Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature. 2012;483(7391):531-533. doi:10.1038/483531a
  87. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nature Reviews Drug Discovery. 2011;10(9):712-712. doi:10.1038/nrd3439-c1
  88. Chen J, Luo X, Qiu H, Mackey V, Sun L, Ouyang X. Drug discovery and drug marketing with the critical roles of modern administration. Am J Transl Res. 2018 Dec 15;10(12):4302-4312. PMID: 30662672; PMCID: PMC6325519.
  89. Hanif M, Babak MV, Hartinger CG. Development of anticancer agents: wizardry with osmium. Drug Discovery Today. 2014;19(10):1640-1648. doi:10.1016/j.drudis.2014.06.016
  90. Chakrabarty R, Mukherjee PS, Stang PJ. Supramolecular Coordination: Self-Assembly of Finite Two- and Three-Dimensional Ensembles. Chemical Reviews. 2011;111(11):6810-6918. doi:10.1021/cr200077m
  91. Hearn JM, Romero-Canelón I, Munro AF, Fu Y, Pizarro AM, Garnett MJ, et al. Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells. Proceedings of the National Academy of Sciences. 2015;112(29). doi:10.1073/pnas.1500925112
  92. Marzo T, La Mendola D. Strike a Balance: Between Metals and Non-Metals, Metalloids as a Source of Anti-Infective Agents. Inorganics. 2021;9(6):46. doi:10.3390/inorganics9060046
  93. Komeda S, Casini A. Next-Generation Anticancer Metallodrugs. Current Topics in Medicinal Chemistry. 2012;12(3):219-235. doi:10.2174/156802612799078964
  94. Muhammad N, Guo Z. Metal-based anticancer chemotherapeutic agents. Current Opinion in Chemical Biology. 2014;19:144-153. doi:10.1016/j.cbpa.2014.02.003
  95. Patra M, Gasser G. Organometallic Compounds: An Opportunity for Chemical Biology? ChemBioChem. 2012;13(9):1232-1252. doi:10.1002/cbic.201200159
  96. Jia S, Wang R, Wu K, Jiang H, Du Z. Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics. Molecules. 2019;24(3):581. doi:10.3390/molecules24030581
  97. Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ. Bidentate Ligands on Osmium(VI) Nitrido Complexes Control Intracellular Targeting and Cell Death Pathways. Journal of the American Chemical Society. 2013;135(38):14060-14063. doi:10.1021/ja4075375
  98. Maillet A, Yadav S, Loo YL, Sachaphibulkij K, Pervaiz S. A novel Osmium-based compound targets the mitochondria and triggers ROS-dependent apoptosis in colon carcinoma. Cell Death & Disease. 2013;4(6):e653-e653. doi:10.1038/cddis.2013.185
  99. Ni WX, Man WL, Cheung MTW, Sun RWY, Shu YL, Lam YW, et al. Osmium(vi) complexes as a new class of potential anti-cancer agents. Chemical Communications. 2011;47(7):2140. doi:10.1039/c0cc04515b
  100. Hildebrandt J, Häfner N, Kritsch D, Görls H, Dürst M, Runnebaum IB, et al. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms. International Journal of Molecular Sciences. 2022;23(9):4976. doi:10.3390/ijms23094976
  101. Romero-Canelón I, Sadler PJ. Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation. Inorganic Chemistry. 2013;52(21):12276-12291. doi:10.1021/ic400835n
  102. Fu Y, Habtemariam A, Pizarro AM, van Rijt SH, Healey DJ, Cooper PA, et al. Organometallic Osmium Arene Complexes with Potent Cancer Cell Cytotoxicity. Journal of Medicinal Chemistry. 2010;53(22):8192-8196. doi:10.1021/jm100560f
  103. Shnyder SD, et al. Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex. Med Chem Comm. 2011;2(7):666–668.
  104. Coverdale JPC, Guy CS, Bridgewater HE, Needham RJ, Fullam E, Sadler PJ. Osmium–arene complexes with high potency towards Mycobacterium tuberculosis. Metallomics. 2021;13(4). doi:10.1093/mtomcs/mfab007
  105. Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene. 2006;25(34):4663-4674. doi:10.1038/sj.onc.1209604
  106. Calvo SE, Tucker EJ, Compton AG, Kirby DM, Crawford G, Burtt NP, et al. High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nature Genetics. 2010;42(10):851-858. doi:10.1038/ng.659
  107. Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, Pandit S, Spencer M, Rabitti C, Fazio VM, Sidransky D. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res. 2001 Oct 15;61(20):7623-6. PMID: 11606403.
  108. Larman TC, DePalma SR, Hadjipanayis AG, The Cancer Genome Atlas Research Network, Protopopov A, Zhang J, et al. Spectrum of somatic mitochondrial mutations in five cancers. Proceedings of the National Academy of Sciences. 2012;109(35):14087-14091. doi:10.1073/pnas.1211502109
  109. Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, et al. Mitochondrial DNA Mutation in Serous Ovarian Cancer: Implications for Mitochondria-Coded Genes in Chemoresistance. Journal of Clinical Oncology. 2012;30(36):e373-e378. doi:10.1200/jco.2012.43.5933
  110. Aikhionbare FO, Mehrabi S, Thompson W, Yao X, Grizzle W, Partridge E. mtDNA sequence variants in subtypes of epithelial ovarian cancer stages in relation to ethnic and age difference. Diagnostic Pathology. 2008;3(1):32. doi:10.1186/1746-1596-3-32
  111. Van Trappen PO, Cullup T, Troke R, Swann D, Shepherd JH, Jacobs IJ, et al. Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecologic Oncology. 2007;104(1):129-133. doi:10.1016/j.ygyno.2006.07.010
  112. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes to Cells. 2001;6(10):857-868. doi:10.1046/j.1365-2443.2001.00469.x
  113. Zhu M, Li W, Lu C. Role of Alpha-Synuclein Protein Levels in Mitochondrial Morphology and Cell Survival in Cell Lines. PLoS ONE. 2012;7(4):e36377. doi:10.1371/journal.pone.0036377
  114. Menazza S, Blaauw B, Tiepolo T, Toniolo L, Braghetta P, Spolaore B, et al. Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. Human Molecular Genetics. 2010;19(21):4207-4215. doi:10.1093/hmg/ddq339
  115. Devine MJ, Plun-Favreau H, Wood NW. Parkinson's disease and cancer: two wars, one front. Nature Reviews Cancer. 2011;11(11):813-823. doi:10.1038/nrc3150
  116. Dalla Pozza E, Fiorini C, Dando I, Menegazzi M, Sgarbossa A, Costanzo C, et al. Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2012;1823(10):1856-1863. doi:10.1016/j.bbamcr.2012.06.007
  117. Pawlak M, Schick E, Bopp MA, Schneider MJ, Oroszlan P, Ehrat M. Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics. 2002 Apr;2(4):383-93. doi:10.1002/1615-9861(200204)2:43.0.CO;2-E. PMID: 12164697.
  118. Ashwell S, Zabludoff S. DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy. Clinical Cancer Research. 2008;14(13):4032-4037. doi:10.1158/1078-0432.ccr-07-5138
  119. Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. ecancermedicalscience. 2019;13. doi:10.3332/ecancer.2019.961
  120. Unger JM, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. American Society of Clinical Oncology Educational Book. 2016:185-198. doi:10.1200/edbk_156686
  121. Mühlgassner G, Bartel C, Schmid WF, Jakupec MA, Arion VB, Keppler BK. Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. Journal of Inorganic Biochemistry. 2012;116:180-187. doi:10.1016/j.jinorgbio.2012.06.003
  122. Gaiddon C, Gross I, Meng X, Sidhoum M, Mellitzer G, Romain B, et al. Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer. Molecules. 2021;26(17):5386. doi:10.3390/molecules26175386
  123. Coverdale JPC, Guy CS, Bridgewater HE, Needham RJ, Fullam E, Sadler PJ. Osmium–arene complexes with high potency towards Mycobacterium tuberculosis. Metallomics. 2021;13(4). doi:10.1093/mtomcs/mfab007
  124. Nabiyeva T, Roufosse B, Odachowski M, Baumgartner J, Marschner C, Verma AK, et al. Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agents. ACS Omega. 2021;6(29):19252-19268. doi:10.1021/acsomega.1c02665
  125. Crochet P, Cadierno V. Arene-Osmium(II) Complexes in Homogeneous Catalysis. Inorganics. 2021;9(7):55. doi:10.3390/inorganics9070055
  126. van Rijt SH, Peacock AFA, Johnstone RDL, Parsons S, Sadler PJ. Organometallic Osmium(II) Arene Anticancer Complexes Containing Picolinate Derivatives. Inorganic Chemistry. 2009;48(4):1753-1762. doi:10.1021/ic8020222
  127. Giorgi E, Binacchi F, Marotta C, Cirri D, Gabbiani C, Pratesi A. Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments. Molecules. 2022;28(1):273. doi:10.3390/molecules28010273
  128. Dragutan I, Dragutan V, Demonceau A. Editorial of Special Issue Ruthenium Complex: The Expanding Chemistry of the Ruthenium Complexes. Molecules. 2015;20(9):17244-17274. doi:10.3390/molecules200917244
  129. Ma DL, Wu C, Wu KJ, Leung CH. Iridium(III) Complexes Targeting Apoptotic Cell Death in Cancer Cells. Molecules. 2019;24(15):2739. doi:10.3390/molecules24152739
  130. Ioele G, Chieffallo M, Occhiuzzi MA, De Luca M, Garofalo A, Ragno G, et al. Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. Molecules. 2022;27(17):5436. doi:10.3390/molecules27175436
  131. Zhu T, Sha Y, Yan J, Pageni P, Rahman MA, Yan Y, et al. Metallo-polyelectrolytes as a class of ionic macromolecules for functional materials. Nature Communications. 2018;9(1). doi:10.1038/s41467-018-06475-9
  132. Huang C, Huang W, Ji P, Song F, Liu T, Li M, et al. A Pyrazolate Osmium(VI) Nitride Exhibits Anticancer Activity through Modulating Protein Homeostasis in HepG2 Cells. International Journal of Molecular Sciences. 2022;23(21):12779. doi:10.3390/ijms232112779
  133. Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. Journal of Nanobiotechnology. 2013;11(1). doi:10.1186/1477-3155-11-26
  134. Hildebrandt J, Häfner N, Kritsch D, Görls H, Dürst M, Runnebaum IB, et al. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms. International Journal of Molecular Sciences. 2022;23(9):4976. doi:10.3390/ijms23094976
  135. Monro S, Colón KL, Yin H, Roque J, Konda P, Gujar S, et al. Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433. Chemical Reviews. 2018;119(2):797-828. doi:10.1021/acs.chemrev.8b00211
  136. Sonkar C, Sarkar S, Mukhopadhyay S. Ruthenium( ii )–arene complexes as anti-metastatic agents, and related techniques. RSC Medicinal Chemistry. 2022;13(1):22-38. doi:10.1039/d1md00220a
  137. Muralisankar M, Chen JR, Haribabu J, Ke SC. Effective and Selective Ru(II)-Arene Complexes Containing 4,4′-Substituted 2,2′ Bipyridine Ligands Targeting Human Urinary Bladder Cancer Cells. International Journal of Molecular Sciences. 2023;24(15):11896. doi:10.3390/ijms241511896
  138. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7-33. doi:10.3322/caac.21654
  139. Feldman DR. Medical Treatment of Advanced Testicular Cancer. JAMA. 2008;299(6):672. doi:10.1001/jama.299.6.672
  140. Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology. 2014;740:364-378. doi:10.1016/j.ejphar.2014.07.025
  141. Sharma P, Jhawat V, Mathur P, Dutt R. Innovation in cancer therapeutics and regulatory perspectives. Medical Oncology. 2022;39(5). doi:10.1007/s12032-022-01677-0
  142. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology. 2020;20(11):651-668. doi:10.1038/s41577-020-0306-5
  143. Cervinka J, Gobbo A, Biancalana L, Markova L, Novohradsky V, Guelfi M, et al. Ruthenium(II)–Tris-pyrazolylmethane Complexes Inhibit Cancer Cell Growth by Disrupting Mitochondrial Calcium Homeostasis. Journal of Medicinal Chemistry. 2022;65(15):10567-10587. doi:10.1021/acs.jmedchem.2c00722
  144. Qin QP, Wang ZF, Huang XL, Tan MX, Shi BB, Liang H. High in Vitro and in Vivo Tumor-Selective Novel Ruthenium(II) Complexes with 3-(2′-Benzimidazolyl)-7-fluoro-coumarin. ACS Medicinal Chemistry Letters. 2019;10(6):936-940. doi:10.1021/acsmedchemlett.9b00098
  145. Legina MS, Nogueira JJ, Kandioller W, Jakupec MA, González L, Keppler BK. Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors. JBIC Journal of Biological Inorganic Chemistry. 2020;25(3):451-465. doi:10.1007/s00775-020-01775-2
  146. Maillet A, Yadav S, Loo YL, Sachaphibulkij K, Pervaiz S. A novel Osmium-based compound targets the mitochondria and triggers ROS-dependent apoptosis in colon carcinoma. Cell Death & Disease. 2013;4(6):e653-e653. doi:10.1038/cddis.2013.185
  147. Domenichini A, Casari I, Simpson PV, Desai NM, Chen L, Dustin C, et al. Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling. Journal of Experimental & Clinical Cancer Research. 2020;39(1). doi:10.1186/s13046-020-01777-7
  148. Bridgewater HE, Bolitho EM, Romero-Canelón I, Sadler PJ, Coverdale JPC. Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors. JBIC Journal of Biological Inorganic Chemistry. 2023;28(3):345-353. doi:10.1007/s00775-023-01994-3
  149. Ma DL, Wu C, Cheng SS, Lee FW, Han QB, Leung CH. Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies. International Journal of Molecular Sciences. 2019;20(2):341. doi:10.3390/ijms20020341
  150. Huang Y, Li X, Zhang Z, Xiong L, Wang Y, Wen Y. Photodynamic Therapy Combined with Ferroptosis Is a Synergistic Antitumor Therapy Strategy. Cancers. 2023;15(20):5043. doi:10.3390/cancers15205043
  151. National Research Council (US) Committee on Prudent Practices in the Laboratory. Prudent Practices in the Laboratory: Handling and Management of Chemical Hazards: Updated Version. Washington (DC): National Academies Press (US); 2011. 4, Evaluating Hazards and Assessing Risks in the Laboratory. Available from: https://www.ncbi.nlm.nih.gov/books/NBK55880/
  152. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Frontiers in Molecular Biosciences. 2020;7. doi:10.3389/fmolb.2020.00193
  153. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. International Journal of Nanomedicine. 2017;Volume12:7291-7309. doi:10.2147/ijn.s146315
  154. Díaz M, Vivas-Mejia P. Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals. 2013;6(11):1361-1380. doi:10.3390/ph6111361
  155. Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. Journal of Hematology & Oncology. 2021;14(1). doi:10.1186/s13045-021-01096-0
  156. Cook N, Hansen AR, Siu LL, Abdul Razak AR. Early phase clinical trials to identify optimal dosing and safety. Molecular Oncology. 2014;9(5):997-1007. doi:10.1016/j.molonc.2014.07.025
  157. Bhatt A. Evolution of clinical research: a history before and beyond james lind. Perspect Clin Res. 2010 Jan;1(1):6-10. PMID: 21829774; PMCID: PMC3149409.
  158. ROSENBERG B, VAN CAMP L, KRIGAS T. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature. 1965;205(4972):698-699. doi:10.1038/205698a0
  159. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug Resistance in Cancer: An Overview. Cancers. 2014;6(3):1769-1792. doi:10.3390/cancers6031769
  160. Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resistance Updates. 2021;59:100796. doi:10.1016/j.drup.2021.100796
  161. Moahamed Sikkander A, Manisankar P , Vedhi C Utilization of sodium montmorillonite clay for enhanced electrochemical sensing of amlodipine,Indian Journal of Chemistry-Section A(IJCA) 55 (5), 571-575DOI: 10.56042/ijca.v55i5.11669
  162. Sivakumar R, Gopalakrishnan P, Abdul Razak MS. Comparative analysis of anti-reflection coatings on solar PV cells through TiO2and SiO2nanoparticles. Pigment & Resin Technology. 2021;51(2):171-177. doi:10.1108/prt-08-2020-0084
  163. Mohamed Sikkander A, Nasri NS., Review on Inorganic Nano crystals unique benchmark of Nanotechnology,Moroccan Journal of Chemistry 1 (2), 1-2 (2013) 47-54.https://doi.org/10.48317/IMIST.PRSM/morjchem-v1i2.1892
  164. Mohamed Sikkander A., Bassyouni F, Yasmeen K, Mishra S.R, Lakshmi V.V. Synthesis of Zinc Oxide and Lead Nitrate Nanoparticles and their Applications: Comparative Studies of Bacterial and Fungal (E. coli, A. Niger). J. Appl. Organomet. Chem., 2023, 3(4), 255-267. https://doi.org/10.48309/JAOC.2023.415886.1115